Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

38
Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
38
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

34
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
34
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

25
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
25
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

30
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
30
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

27
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
27
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

71
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
71

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Routinely Available Inflammatory Biomarkers Are Not Associated With Target Lesion Revascularization After Coronary Intervention.

JACC. Advances·2025
Same author

The Prognostic Interplay of Heart Failure and Chronic Kidney Disease in Atrial Fibrillation - Focus on Cardiorenal Outcomes.

Cardiorenal medicine·2025
Same author

The 6-min walk test in transthyretin cardiac amyloidosis: prognostic utility put to the real-world test.

Frontiers in medicine·2025
Same author

Implementation of Medical Therapy in Different Stages of Heart Failure with Reduced Ejection Fraction: An Analysis of the VIENNA-HF Registry.

Biomedicines·2025
Same author

Mitochondrial ROS drive foam cell formation via STAT5 signaling in atherosclerosis.

Science advances·2025
Same author

Association between CMR-derived hepatic T1-time, tricuspid regurgitation and survival.

European journal of clinical investigation·2025

Related Experiment Video

Updated: Aug 26, 2025

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve
09:13

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve

Published on: June 14, 2017

12.9K

Metabolomics implicate eicosanoids in severe functional mitral regurgitation.

Thomas M Hofbauer1, Klaus Distelmaier1,2, Besnik Muqaku3

  • 1Department of Cardiology, Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.

ESC Heart Failure
|October 11, 2022
PubMed
Summary

Metabolomic profiling revealed elevated eicosanoids in patients with severe functional mitral regurgitation (FMR), a condition linked to heart failure with reduced ejection fraction (HFrEF). Elevated 8,9-DiHETrE levels independently predicted mortality in these patients.

Keywords:
EicosanoidsFunctional mitral regurgitationHeart failureMetabolomics

More Related Videos

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

622
A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.0K

Related Experiment Videos

Last Updated: Aug 26, 2025

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve
09:13

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve

Published on: June 14, 2017

12.9K
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

622
A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.0K

Area of Science:

  • Cardiology
  • Metabolomics
  • Biochemistry

Background:

  • Functional mitral regurgitation (FMR) is a recognized complication of heart failure with reduced ejection fraction (HFrEF), associated with poor outcomes.
  • Current therapeutic strategies for FMR are limited due to an incomplete understanding of its progression mechanisms.
  • Metabolic derangements in FMR are poorly understood, necessitating further investigation.

Purpose of the Study:

  • To conduct metabolomic profiling of patients with heart failure with reduced ejection fraction (HFrEF) and severe functional mitral regurgitation (FMR).
  • To compare metabolite profiles between HFrEF patients with severe FMR and those with no or mild FMR.
  • To identify potential biomarkers for FMR progression and associated mortality risk.

Main Methods:

  • Plasma samples were collected from 80 HFrEF patients on guideline-directed medical therapy.
  • Targeted plasma metabolomics and untargeted eicosanoid analyses were performed.
  • Statistical analyses accounted for age, body mass index, and sex to compare eicosanoid and metabolite levels between groups.

Main Results:

  • Six eicosanoids were significantly up-regulated in patients with severe FMR compared to those with no or mild FMR.
  • No significant differences were observed in other measured metabolites between the groups.
  • Elevated levels of 8,9-DiHETrE in severe FMR patients independently predicted all-cause mortality over a median follow-up of 43 months.

Conclusions:

  • This study reports the up-regulation of specific eicosanoids, including 8,9-DiHETrE, in patients with severe FMR.
  • 8,9-DiHETrE emerged as a potential independent predictor of mortality in severe FMR patients.
  • These findings provide a basis for further research into the metabolic underpinnings of FMR and its clinical implications.